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CLINICAL CASE
This is a case of a 50-year-old woman complaining of easy fatigability, anorexia and hypotension since
2009. She also reported alopecia, a 15 kg weight loss, and amenorrhea. A year after the beginning of
the symptoms she sought medical attention: a diagnosis of nephrotic syndrome with proteinuria
.10 g/L was made. A renal biopsy showed focal segmental glomerulosclerosis. Steroids and
cyclosporin were then started. The patient did quite well until November 2011 when she was
hospitalized for the recurrence of the symptoms. Because of persistent hypotension, Rituximab therapy
instead of Bortezumib was instituted. At that time the ECG showed sinus rhythm with low QRS voltages
and Q waves in the inferior leads and from V1 to V4. An echocardiogram showed severe symmetric left
ventricular hypertrophy (21mm of the interventricular septum and 20mm of the posterior wall diastolic
thickness). The left ventricular walls showed an inhomogeneous granular pattern. During systole, a
virtual left ventricular cavity was evident with a left ventricular ejection fraction (LVEF) around 60%.
A severe dynamic left ventricular outflow tract (LVOT) obstruction was present with a left ventricular-
aortic gradient of 120mmHg at rest and 250mmHg during the Valsalva maneuver. Moderate mitral
regurgitation with a systolic anterior motion (SAM) of the mitral valve was demonstrated. Severe
diastolic dysfunction was present, with an E/E’ ratio of 12.3 cm/s (Figure 1).
The clinical and echocardiographic picture raised the diagnostic issue of a systemic amyloidosis with
cardiac involvement or the presence of hypertrophic cardiomyopathy (HCM) in a patient with nephrotic
syndrome. No family history of HCM was reported. To establish a correct diagnosis a more detailed
work-up was then carried out: the renal biopsy specimens were reanalyzed with the Congo red staining
and resulted positive for amyloid fibrils (Figure. 2). A diagnosis of l light chain (AL) systemic
amyloidosis was entertained based on the results of the immunological blood work (monoclonal
immunoglobulin on urine and serum, serum immunofixation, quantitative measurement of serum k
and l free light chains) and the results of the abdominal fat aspiration and bone marrow biopsies
which were positive for amyloid. In addition, a cardiac magnetic resonance imaging (MRI)
demonstrated, with the late gadolinium subendocardial enhancement (LGE), an endocardial-epicardial
signal intensity gradient typical for heart amyloidosis, with the early gadolinium clearance from the
blood pool. This pattern of gadolinium distribution suggested cardiac amyloidosis (Figure 1). At this
point the diagnosis of systemic amyloidosis with a cardiac involvement seemed to be corroborated.
Therefore therapy with cyclophosphamide, thalidomide and dexamethasone was initiated. However,
for the completeness of a diagnostic work up, a genetic typing test for HCM was also sent to the lab.
After an initial clinical improvement, the patient experienced symptoms of severe heart failure. She
was hospitalized and Bortezumib was started. Unfortunately the renal function progressively worsened
and dialysis was necessary. After three cycles of chemotherapy the patient improved her functional
class and was discharged home on dialysis three times a week. No more episodes of heart failure
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occurred in the follow-up. Follow-up echocardiography at 3, 6 and 12 months demonstrated a gradual
improvement. The 12-month echocardiogram showed a reduced septal thickness of 17mm and the
peak LVOT gradient decreased significantly from 120mmHg to 15mmHg at rest without an increase
with the Valsalva maneuver. LVEF improved to 70%, mitral regurgitation was mild with no more
evidence of SAM and diastolic dysfunction improved to a pseudonormal filling pattern with a E/E’ ratio
of 10 cm/s.
Surprisingly, the results of the genetic typing came back positive for a double heterozygous mutation
on p.Arg1079Gln for MYH7 gene (suggesting HCM) and on p.Cys566Ser for MYBPC3 (a novel mutation,
never described in the literature, in a highly conserved amino acid).
At the present time the patient is doing well with diuretic therapy (Furosemide 50mg per day,
Spironolactone 25mg per day, potassium chloride 600mg tid), prednisone and chemotherapy cycles.
DISCUSSION
AL amyloidosis is an uncommon disease with a dire prognosis.1–3 Cardiac involvement is usually
part of a systemic disease; when heart failure develops, death can ensue within 4–6 months.4–5
By contrast, HCM is relatively common with a more favorable prognosis.6 The presence of LVOT
obstruction has been reported only in a few cases of amyloidosis7–11 and the AL type amyloidosis
is probably the rarest one. In addition the LVOT gradients described are not as high as it was in
our patient.
Differential diagnosis between cardiac amyloidosis and HCM is mandatory since the prognosis is
very different. Our patient experienced symptoms and signs of nephrotic syndrome associated to
Figure 2. Renal biopsy. Light microscopy of hematoxylin and eosin-stained kidney showing infiltration by
collagen-type extracellular material (F). Polarized microscopy of Congo red-stained kidney showing apple-green
birefringence, diagnostic of amyloid (G).
Figure 1. ECG showing sinus rhythm, low QRS voltages, Q waves on the inferior leads and on V1-V4 (A).
Echocardiography showing increased ventricular mass and granular sparkling pattern (B) and severe LVOT
gradient on Continuous-wave Doppler (C). Decreased LVOT gradient after starting chemotherapy (D). MRI: LGE
image demonstrating an endocardial-epicardial signal gradient and disappearance of the contrast agent from
the blood pool (E).
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episodes of heart failure. The ECG demonstrated low QRS voltages with pathological Q waves in the
inferior and anterior leads pointing towards an infiltrative disease. However, the echocardiographic
findings of severe septal wall thickness, the presence of SAM of the mitral valve with mitral
regurgitation and the demonstration of a dynamic LVOT gradient suggested a diagnosis of HCM,
whereas the typical granular appearance of the cardiac walls favored a cardiac involvement of systemic
amyloidosis (Figure 1).12 The clinical picture, the ECG and the echocardiographic findings were
somewhat discordant. To settle the diagnostic issue a cardiac MRI was performed. The LGE images
demonstrated a circumferential endocardial-epicardial signal gradient typical for amyloid infiltration.
As an extracellular fluid tracer, gadolinium accumulates in expanded interstitial spaces, which are
increased secondary to extracellular amyloid infiltration. This behavior determines the early gadolinium
disappearance from the blood pool (Figure 1). These features are highly sensitive and specific for
amyloid involvement of the heart.13 A diagnosis of systemic amyloidosis with a cardiac involvement
was favored and, in addition to heart failure treatment, the patient was started on chemotherapy for the
systemic amyloidosis (Cyclophosphamide, Bortezumib and Dexamethasone cycles) to which she
responded very well. Surprisingly, genetic typing resulted positive for a double heterozygous mutation
on p.Arg1079Gln for MYH7 gene and on p.Cys566Ser for MYBPC3, diagnostic of HCM. The positivity of
genetic testing for mutations diagnostic of HCM raises the question of the clinical meaning of the
genetic testing. To our knowledge the possible coexistence of amyloidosis and HCM has never been
described in the literature. It seems unclear if we face a case of cardiac amyloidosis with a positive
genetic typing for HCM without a real phenotypic expression or, on the other hand, we assist to an
atypical clinical presentation of HCM in a patient with systemic amyloidosis. The answer is difficult and
maybe only the clinical follow-up will clarify the issue. Moreover, the role of the novel mutation in a
highly conserved amino acid has to be followed out.
CONCLUSIONS
To our knowledge, this is the first reported case of a patient with cardiac involvement of systemic
amyloidosis and genotyped HCM presenting with neprothic syndrome and heart failure.
The multimodality diagnostic approach including ECG, echocardiogram, renal and abdominal fat
biopsies, cardiac MRI and the genetic testing allowed to diagnose the presence of both the diseases in
the same patient.
The predominant role of one pathology versus the other one in determining the clinical scenario and
the response to the treatment has not been completely clarified yet.
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